Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus

Abstract

Individuals suffering from systemic lupus erythematosus (SLE) are predisposed to accelerate cardiovascular disease. Our laboratory has recently developed an animal model of SLE-accelerated atherosclerosis. We have shown that, following 8 weeks feeding high fat Western diet, radiation chimeras consisting of SLE-derived haematopoietic cells transferred to low-density lipoprotein (LDL)r^−/− mice (LDLr.Sle) have increased atherosclerosis compared with C57Bl/6 bone marrow recipients (LDLr.B6). However, this feeding regimen resulted in significant mortality in SLE-susceptible mice compared with controls with surviving animals having extremely elevated serum cholesterol (>500 mg/dL) and increased serum markers of kidney pathology. To test the hypothesis that SLE-associated autoimmune dysregulation can exacerbate atherosclerosis under more mild serum cholesterol conditions (approximately 200 mg/dL), we examined SLE and lesion development in radiation chimeras fed either a normal chow or high fat Western diet for 8 weeks. High fat fed LDLr.Sle mice exhibited increased mortality and were significantly more hypertensive. LDLr.Sle mice had greater titres of antibodies against dsDNA, oxLDL and phospholipid compared with controls. Lupus-susceptibility increased the atherosclerotic lesions and the percentage of CD4⁺ T cells in the lesions of proximal aortas, independent of diet. These data show that increased dyslipidemia resulting from high-fat feeding can exacerbate autoimmunity and associated vascular complications. Conversely, they also show that autoimmune dysregulation can accelerate atherosclerosis in LDLr-deficient animals independent of feeding high fat diet. Collectively this study provides additional evidence that the accelerated atherosclerosis observed in SLE is autoimmune associated.

Keywords

atherosclerosis autoimmunity high fat diet lupus

Get full access to this article

View all access options for this article.

References

1 Ward MM Pyun E Studenski S . Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995; 8: 1492–1499.

2 Aranow C Ginzle EM . Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000; 9: 166–169.

3 Lockshin MD Salmon JE Roman MJ . Atherosclerosis and lupus: a work in progress. Arthritis Rheum 2001; 44: 2215–2217.

4 Chiu YH Jayawardena J Weiss A . Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 1999; 189: 103–110.

5 Glass C Witzaum J . Atheroscleroisis. the road ahead. Cell 2001; 104: 503–516.

6 Morel L Rudofsky UH Longmate JA Schiffenbauer J Wakeland EK . Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994; 1: 219–229.

7 Mohan C Morel L Yang P Wakeland EK . Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997; 159: 454–465.

8 Mohan C Alas E Morel L Yang P Wakeland EK . Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101: 1362–1372.

9 Mohan C Yu Y Morel L Yang P Wakeland EK . Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999; 162: 6492–6502.

10.

10 Morel L Mohan C Yu Y . Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997; 158: 6019–6028.

11.

11 Morel L Yu Y Blenman KR Caldwell RA Wakeland EK . Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome 1996; 7: 335–339.

12.

12 Sobel ES Mohan C Morel L Schiffenbauer J Wakeland EK . Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells. J Immunol 1999; 162: 2415–2421.

13.

13 Sobel ES Morel L Baert R Mohan C Schiffenbauer J Wakeland EK . Genetic dissection of systemic lupus erythematosus pathogenesis: evidence for functional expression of Sle3/5 by non-T cells. J Immunol 2002; 169: 4025–4032.

14.

14 Stanic AK Stein CM Morgan AC . Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2006; 103: 7018–7023.

15.

15 Major AS Fazio S Linton MF . B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002; 22: 1892–1898.

16.

16 Delgado Alves J Ames PR Donohue S . Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686–2694.

17.

17 Delgado Alves J Kumar S Isenberg DA . Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2003; 42: 893–899.

18.

18 Aprahamian T Bonegio R Rizzo J . Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006; 177: 3028–3034.

19.

19 Gautier EL Huby T Ouzilleau B . Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler Thromb Vasc Biol 2007; 27: 1625–1631.

20.

20 Aprahamian T Rifkin I Bonegio R . Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 2004; 199: 1121–1131.

21.

21 Roman MJ Shanker BA Davis A . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–2406.

22.

22 Roman MJ; Salmon JE; Sobel R; . Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001; 87: 663–666, A611.

23.

23 Morrow WJ Ohashi Y Hall J . Dietary fat and immune function. I. Antibody responses, lymphocyte and accessory cell function in (NZB × NZW)F1 mice. J Immunol 1985; 135: 3857–3863.

24.

24 Lin BF Jeng SJ Chiang BL Huang CC . Dietary fat affects lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr 1997; 77: 657–669.

25.

25 Lin BF Huang CH Chiang BL Jeng SJ . Dietary fat influences Ia antigen expression, cytokines and prostaglandin E2 production of immune cells in autoimmune-prone NZB × NZW F1 mice. Br J Nutr 1996; 75: 711–722.

26.

26 Yumura W Hattori S Morrow WJ Mayes DC Levy JA Shirai T . Dietary fat and immune function. II. Effects on immune complex nephritis in (NZB × NZW)F1 mice. J Immunol 1985; 135: 3864–3868.

27.

27 Tisseverasinghe A Lim S Greenwood C Urowitz M Gladman D Fortin PR . Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2211–2219.

28.

28 McMahon M Hahn BH . Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 2007; 19: 633–639.

29.

29 McMahon M Grossman J FitzGerald J . Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541–2549.

30.

30 Thiagarajan P . Atherosclerosis, autoimmunity, and systemic lupus erythematosus. Circulation 2001; 104: 1876–1877.

31.

31 Vuilleumier N Reber G James R . Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004; 23: 353–360.

32.

32 Svenungsson E Jensen-Urstad K Heimburger M . Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–1893.

33.

33 Zhou X Paulsson G Stemme S Hansson GK . Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apoE-knockout mice. J Clin Invest 1998; 101: 1717–1725.

34.

34 de Geest B Collen D . Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease. Eur Heart J 2001; 22: 1517–1518.

35.

35 Wu JT Wu LL . Autoantibodies against oxidized LDL. A potential marker for atherosclerosis. Clin Lab Med 1997; 17: 595–604.

36.

36 Steinerova A Racek J Stozicky F Zima T Fialova L Lapin A . Antibodies against oxidized LDL–theory and clinical use. Physiol Res 2001; 50: 131–141.

37.

37 Paiker JE Raal FJ von Arb M . Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem 2000; 37: 174–178.

38.

38 Kobayashi K Tada K Itabe H . Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 2007; 16: 929–938.

39.

39 George J Harats D Gilburd B . Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102: 1822–1827.

Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus–susceptible LDLr−/− mice

Abstract

Keywords

Get full access to this article

References